Payment overview · 2025
General Payments
$1,250.92
64 reported records · 15 companies
Healthcare provider profile · identity verified
William Stephen Knapp, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FLORISSANT, MO · NPI 1023099140
Verified facts
What the public records show
CMS Open Payments records show William Stephen Knapp, D.O. received $1,250.92 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $387.32 | 31.0% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $200.20 | 16.0% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $162.05 | 12.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $128.55 | 10.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.53 | 6.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.05 | 6.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.93 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.90 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.06 | 2.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.80 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.61 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.62 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.66 | 1.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.50 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.14 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,250.92 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $357.50 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $196.09 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.73 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.71 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.27 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $75.05 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.65 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.01 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.27 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $55.86 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 56 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 173 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
56 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 36 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 744 | 221 |
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 487 | 147 |
| Lisinopril | Lisinopril | 478 | 138 |
| Alprazolam | Alprazolam | 463 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 450 | 76 |
| Gabapentin | Gabapentin | 344 | 111 |
| Furosemide | Furosemide | 334 | 101 |
| Alendronate Sodium | Alendronate Sodium | 284 | 79 |
| Omeprazole | Omeprazole | 269 | 76 |
| Losartan Potassium | Losartan Potassium | 258 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 64 |
| Sertraline Hcl | Sertraline Hcl | 234 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 76 |
| Metformin Hcl | Metformin Hcl | 222 | 68 |
| Tramadol Hcl | Tramadol Hcl | 220 | 64 |
| Irbesartan | Irbesartan | 206 | 58 |
| Lorazepam | Lorazepam | 204 | 53 |
| Meloxicam | Meloxicam | 204 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 63 |
| Naproxen | Naproxen | 180 | 64 |
| Eliquis | Apixaban | 173 | 34 |
| Prednisone | Prednisone | 172 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 53 |
| Simvastatin | Simvastatin | 167 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 43 |
| Jardiance | Empagliflozin | 154 | 36 |
| Glimepiride | Glimepiride | 142 | 44 |
| Ozempic | Semaglutide | 142 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 24 |
| Celecoxib | Celecoxib | 134 | 39 |
| Allopurinol | Allopurinol | 133 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 125 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 31 |
| Carvedilol | Carvedilol | 116 | 30 |
| Trazodone Hcl | Trazodone Hcl | 114 | 35 |
| Methylprednisolone | Methylprednisolone | 109 | 98 |
| Azelastine Hcl | Azelastine Hcl | 100 | 23 |
| Levofloxacin | Levofloxacin | 100 | 52 |
| Montelukast Sodium | Montelukast Sodium | 100 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 44 |
| Azithromycin | Azithromycin | 97 | 82 |
| Donepezil Hcl | Donepezil Hcl | 96 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 69 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 18 |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 23 |
| Finasteride | Finasteride | 77 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 20 |
| Meclizine Hcl | Meclizine Hcl | 73 | 28 |
| Memantine Hcl | Memantine Hcl | 72 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 58 |
| Methocarbamol | Methocarbamol | 68 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 59 |
| Spironolactone | Spironolactone | 66 | 24 |
| Methotrexate | Methotrexate Sodium | 65 | 16 |
| Mirtazapine | Mirtazapine | 65 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 52 |
| Folic Acid | Folic Acid | 63 | 19 |
| Ibuprofen | Ibuprofen | 63 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 59 | 17 |
| Metformin Hcl Er | Metformin Hcl | 59 | 22 |
| Glipizide | Glipizide | 58 | 17 |
| Xarelto | Rivaroxaban | 58 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 56 | 56 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Fenofibrate | Fenofibrate | 56 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 11 |
| Famotidine | Famotidine | 54 | 14 |
| Pregabalin | Pregabalin | 53 | 13 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 17 |
| Benzonatate | Benzonatate | 48 | 39 |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 11 |
| Cephalexin | Cephalexin | 46 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 43 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Mupirocin | Mupirocin | 34 | 18 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 11 |
| Atenolol | Atenolol | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 27 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 13 |
| Temazepam | Temazepam | 27 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 23 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Junel | Norethindrone Ac/Eth Estradiol | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,250.92 · 64 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEXSERO, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error